Abstract Ambulatory blood pressure (BP) monitoring provides valuable information on a person's BP phenotype. Abnormal ambulatory BP phenotypes include white-coat hypertension, masked hypertension, nocturnal nondipping, nocturnal hypertension, and high BP variability. Compared to people with sustained normotension (normal BP in the clinic and on ambulatory BP monitoring), the limited research available suggests that the risk of developing sustained hypertension (abnormal BP in the clinic and on ambulatory BP monitoring) over 5 to 10 years is approximately two to three times greater for people with white-coat or masked hypertension. More limited data suggest that nondipping might predate hypertension, and no studies, to our knowledge, have examined whether nocturnal hypertension or high ambulatory BP variability predict hypertension. Ambulatory BP monitoring may be useful in identifying people at increased risk of developing sustained hypertension, but the clinical utility for such use would need to be further examined.
Introduction
Hypertension is one of the most important risk factors for cardiovascular disease (CVD), which remains the leading cause of death in America [1•] . In the United States of America (USA), on average, the risk of developing hypertension over a lifetime is approximately 90 % [2] . The short-term risk of incident hypertension is highest for Blacks and lowest for Whites up until 75 years of age [new 3 ]. An estimated 40 % of CVD mortality is due to high blood pressure [1•] . Thus, primary prevention of hypertension is an important public health goal [4] . Primary prevention of hypertension from a clinical standpoint consists of identifying patients who are "pre-hypertensive" and counseling them to lose weight if warranted, reduce sodium intake, adopt the Dietary Approaches to Stop Hypertension (DASH) eating plan [5] , exercise, and limit alcohol intake [6] . While these lifestyle changes can help prevent or delay the onset of hypertension, clinical effectiveness at getting patients with "prehypertension" to adopt them is extremely limited [7] [8] [9] .
In addition to the category of prehypertension itself [6] , several risk scores for hypertension have been developed [10•] . The underlying basis for developing such scores is that targeting people most at risk in the shorter term might increase the effectiveness of preventive interventions such as lifestyle recommendations. Identifying those at higher risk may also permit use of more aggressive interventions such as specialized weight loss or exercise programs. People whose short-term risk is increased can also be monitored more closely for development of hypertension. Not surprisingly, in all of the hypertension risk models, a person's blood pressure (BP) level is one of the most important predictors [10•] .
Through the use of 24-h ambulatory BP monitoring [11] , it has become evident that people exhibit several BP patterns (Table 1 ). The pairing of office BP measurement(s) with average BP derived from ambulatory BP data yields four major phenotypes of BP: sustained normotension, white-coat hypertension, masked hypertension, and sustained hypertension (Table 2) . Ambulatory BP monitoring also uniquely provides measures of BP during sleep which can be used to calculate mean sleep BP. Normally during sleep, BP decreases ("dips") such that sleep BP average is lower than awake BP average (Fig. 1) . The "normal" dip is considered 10-20 % [12•]. Individuals who dip <10 % are said to exhibit the nondipper phenotype (although this category includes "mild dippers" who dip but do so less than 10 %). Nondippers whose sleep BP average is actually greater than their awake BP average are described as "risers," and dippers who exceed 20 % are sometimes referred to as "extreme dippers." Ambulatory BP measurements can also be used to derive other measures of variability such as standard deviation and average real variability [13] . Thus, "high ambulatory BP variability" represents another phenotype.
While we are aware of no risk score that incorporates ambulatory BP, people with abnormal BP phenotypes might be at greater risk of developing sustained hypertension than people whose BP pattern is considered normal or optimal. Herein, we summarize relevant literature examining the risk of developing sustained hypertension according to baseline ambulatory BP phenotype. Given the limited data available, we also included studies that categorized baseline BP phenotype using home BP monitoring.
Defining Incident Hypertension
For the purpose of this paper, we preferred studies that examined incident hypertension based on 24-h ambulatory BP monitoring. Often, such studies would also include measurements of BP taken in the office setting. As shown in Table 2 , when office BP and ambulatory or home BP average are both elevated, the term "sustained" hypertension is used. Incident hypertension could also be based on office BP readings alone if 24-h ambulatory BP or home BP was not available. However, in such instances, it is impossible to know whether the incident hypertension is white-coat or sustained.
Phenotypes and Risk for Sustained Hypertension

Sustained Normotension
Sustained normotension is defined as non-elevated office BP (<140/90 mmHg) and normal ambulatory BP (i.e., daytime ambulatory BP average <135/85 mmHg or 24-h ambulatory BP average <130/80 mmHg) or home BP average <135/ 85 mmHg. Compared to persons with abnormal BP phenotypes discussed below, a person with sustained normotension, especially if office BP is optimal (i.e., <120/80 mmHg) by conventional standards, has the lowest risk of developing hypertension, at least in the short-term. For example, one study showed that among people with sustained normotension at baseline, approximately 18 % had sustained hypertension 10 years later [14•] . In another study conducted in Japan that used home BP measurements for out-of-office assessments, 22 % of adults 40 years and older who had sustained (home BP) normotension at baseline had developed sustained (home BP) hypertension (elevated office BP defined as ≥140/90 mmHg, and elevated home BP defined as ≥135/85 mmHg or start of treatment with antihypertensive medication) 8 years later [15] .
White-Coat Hypertension
White-coat hypertension is said to be present when office BP is elevated (≥140/90 mmHg) with normal ambulatory BP (i.e., daytime ambulatory BP <135/85 mmHg or 24-h ambulatory BP <130/80 mmHg) or home BP (<135/85 mmHg).
In the PAMELA study, Mancia and colleagues examined 1,412 adults whose ages ranged from 25 to 74 years at baseline. Participants had office visit BP measurements and 24-h ambulatory BP monitoring at baseline and 10 years later [14•] . At baseline, there were 758 participants categorized as Average absolute difference between consecutive readings over the 24 h; "high" variability usually defined as the highest percentile (e.g., quartile) in the sample sustained normotensive and 225 categorized as white-coat hypertensive. Of the participants with white-coat hypertension at baseline, 43 % had sustained hypertension 10 years later compared to 18 % among those with sustained normotension at baseline. After adjusting for age and sex, and excluding any participants on BP-lowering medications, the odds of developing sustained hypertension were approximately three times that of those with sustained normotension (adjusted odds ratio (aOR) 3.25; 95 % CI 2.08-5.07). A similar percentage was noted in the Japanese home BP measurement study mentioned above, in which 47 % of those with white-coat hypertension at baseline had developed sustained (home BP) hypertension 8 years later [15] . After adjustment for multiple confounders, the odds ratio for development of sustained (home BP) hypertension was 2.9 (95 % CI 1.9-4.3) [15] .
Masked Hypertension
People whose office BP is <140/90 mmHg but whose 24-h ambulatory BP or home BP average is elevated (Table 1) are classified as having masked hypertension. In the PAMELA study described above, of the participants with masked hypertension at baseline (n=124), 47 % had sustained hypertension 10 years later [14•] . After adjusting for age and sex, and excluding any participants taking BP-lowering medications, the odds of developing sustained hypertension were approximately 1.7 times that of those with sustained normotension (aOR 1.65; 95 % CI 1.27-2.15). In another study of 1,669 white-collar workers, 232 had masked hypertension at baseline [16•] . At 3 years, 26 % of those with masked hypertension had sustained hypertension, and at 5 years, 35 % had sustained hypertension. Another study with average follow-up of 6 to 7 years found a 42 % incidence of sustained hypertension among adults with masked hypertension compared to a 17 % incidence among those with sustained normotension [17] .
Nondipping Pattern
As mentioned earlier, a nondipping pattern is defined as sleep BP average that decreases less than 10 % relative to awake Note that classification is based on either systolic, diastolic, or both a 135/85 mmHg if only awake measurements from 24-h ambulatory BP data used Fig. 1 A 24-h ambulatory blood pressure monitoring graph. The 24-h period of monitoring is divided primarily into awake (often called "daytime") and sleep (often called "nocturnal") periods (shaded section in above graph). Sometimes, to improve tolerability of wearing the monitor, readings are taken at less frequent intervals during the sleep period. A diary is often used as the basis by which to define sleep time, although some studies use a specified period (e.g., midnight to 6 a.m.) to denote sleep time. Based on the time periods, a person's awake (or daytime) BP average can be calculated, as can their sleep (or nocturnal) average. Shown above is the graph of a person whose awake average (based on 31 measurements) was 128/81 mmHg (±14/11) and sleep average (based on 7 measurements) was 108/64 mmHg (±13/11). The nocturnal systolic dip is calculated as (128-108)/128, which is approximately 16 %. The lowest line on the graph shows heart rate ambulatory BP average. It has been suggested that nondipping in younger adults might predate hypertension, possibly due to an early autonomic imbalance as a contributor [18] . In one analysis of 264 adults (mean age 30 years) who had ambulatory BP monitoring, 118 were nondippers [18] . Baseline office BP was 107/72 mmHg. Over a follow-up of 15 years, the incidence of a change to office prehypertension or hypertension was 36/ 1,000 person-years (64 out of 118) among non-dippers compared to 29/1,000 person-years (64 out of 146) among dippers. When adjusted for race, age, baseline clinic BP, and other factors, the difference was not significant. However, the study was limited by a small sample size as well as office BP that was low at baseline. Additionally, participants did not have followup ambulatory BP monitoring, so it is not known whether participants with incident hypertension had sustained or white-coat hypertension.
Nocturnal Hypertension
Nocturnal hypertension is defined as sleep BP average of ≥120/70 mmHg during ambulatory BP monitoring. It can occur with daytime (awake) hypertension or in isolation [19] . It can also occur in dippers or nondippers but appears superior to nondipping status as a predictor of cardiovascular disease risk [20] . We are aware of no studies that have examined the incidence of sustained hypertension according to baseline nocturnal hypertension status.
High Ambulatory BP Variability
Ambulatory BP variability can be reported as a standard deviation of the BP readings from the 24-h period or as average real variability (ARV). ARV is calculated as the average absolute difference between consecutive readings over the 24 h and therefore is sensitive to the order of BP measurements over the monitoring period. "High" variability is usually defined as the highest percentile (e.g., quartile) in the sample being studied. On ABPM, ARV is a better predictor of cardiovascular risk than the traditional SD [13, 21] . While research shows that higher ARV is associated with cardiovascular disease [22] , we are aware of no studies that have examined the incidence of hypertension according to levels of ARV.
Discussion
While there are a number of studies that demonstrate the increased CVD-related risk associated with certain abnormal ambulatory BP phenotypes [22, 23•, 24, 25, 26•, 27 ], few studies have examined the risk of hypertension according to these phenotypes. Despite relatively limited data, however, it does appear that people with white-coat or masked hypertension are at two to three times the risk of developing sustained hypertension over 5 to 10 years compared to those with sustained normotension. It also appears that people with normal ambulatory BP averages but a nondipping nocturnal BP pattern may be at increased risk of developing hypertension. We are aware of no studies that examined the risk of sustained hypertension associated with nocturnal hypertension or across strata of ambulatory BP variability. Studies that have used home BP instead of ambulatory BP monitoring have found similar results, although it is not certain that these methods are interchangeable for identifying out-of-office BP phenotypes [28] . In current US clinical practice, most people who have ambulatory BP do so for evaluation of possible white-coat effect. Most evidence demonstrates that people with whitecoat hypertension have CVD risk similar to, or only slightly greater than, people with true normotension, and therefore do not need to be offered BP-lowering medications [27, 29] . Given the increased short-term risk of sustained hypertension, it seems prudent to monitor such patients more closely for development of hypertension. Additionally, a push for more aggressive lifestyle modifications may be worthwhile. Masked hypertension poses a different challenge. If a person is identified as having masked hypertension, BP-lowering treatment might actually be warranted based on the fact that the CVD risk among such patients approaches that of those with sustained hypertension. However, there are currently no trials that have demonstrated a reduction in CVD events by treating masked hypertension. It seems clear at the very least that such patients should be monitored closely for development of sustained hypertension.
In addition to the small number of studies that have examined the incidence of hypertension according to ambulatory BP phenotypes, the existing research has a number of limitations. Studies have been limited in terms of the population enrolled. For example, studies may have only included only Caucasians (PAMELA) [14•] . Given that Blacks have a higher prevalence and severity of hypertension, the risk based on ambulatory BP phenotype may differ. We know, for instance, that Blacks have a higher prevalence of nondipping [18] .
A systematic review of hypertension risk models is notable for the fact that no models include baseline ambulatory BP measures [10•] . Risk prediction might be refined by including such measures. An additional important point to note about research on hypertension risk is that any study that categorizes incident hypertension solely by office BP is limited as it would not necessarily reflect sustained hypertension.
Conclusions
People with white-coat and masked hypertension are two to three times more likely to develop sustained hypertension over 5 to 10 years. It also appears that nondipping might be a harbinger of developing hypertension. We know of no studies examining whether nocturnal hypertension or high ambulatory BP variability among people with otherwise normal ambulatory BP average predict hypertension. In addition to its value in diagnosis and management of hypertension, ambulatory BP monitoring may be useful in identifying some groups at increased short-term risk of developing hypertension. Further research is needed to learn whether such use is clinically effective at preventing or delaying hypertension.
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